The FDA Just Created a Secret Fast Lane for Drug Factories
The FDA just picked seven companies for a brand-new program that lets them get regulatory feedback on drug factories *while they're still being built*. It could save up to 14 months on approvals, and the list of who got in tells you exactly where the industry is headed.
Imagine building a restaurant, spending $500 million on the kitchen, and then finding out on opening night that the health inspector wants you to move every sink. That's basically what happens in biotech manufacturing. Companies spend years and billions constructing facilities to make complex drugs, only to discover during the FDA's final review that something needs to change.
The FDA just decided to fix that. And only seven companies got the golden ticket.
The Chosen Seven
On June 29, the FDA named the first cohort of participants in its PreCheck Pilot Program: Eli Lilly, Regeneron, Amneal Pharmaceutical, Cellares Corp., FUJIFILM Biotechnologies, Kriya Therapeutics, and Kyowa Kirin. These seven companies will get something no one else has ever received: early, structured FDA feedback on their manufacturing facilities while those facilities are still being built.
The roster is fascinating. It ranges from Eli Lilly (the most valuable healthcare company on the planet) to Cellares and Kriya Therapeutics, closely held biotechs working on gene therapies and automated cell processing. The majority of them plan to make biologic drugs or genetic medicines, which involve the most complex manufacturing in pharma.
That's not a coincidence. It's the whole point.
Why Drug Factories Are the Real Bottleneck
When people think about drug approvals, they think about clinical trials. Did the drug work? Was it safe? But there's a quieter, less glamorous reason drugs get delayed: the factory isn't ready.
For biologics and gene therapies, manufacturing isn't like stamping out pills. These products are grown in living cells, processed through intricate purification steps, and stored under conditions that would make a wine collector nervous. The facilities that make them need specialized cleanrooms, closed systems, and validated quality controls at every step.
Traditionally, the FDA evaluates all of this near the end of the approval process through what's called a pre-approval inspection (PAI). If inspectors find significant problems, the company gets a Complete Response Letter, which is the FDA's polite way of saying "not yet." A failed inspection often means a second inspection cycle, adding months or even years to the timeline.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
This is where drugs go to wait. And for the most complex products, it's where billions in investment sit idle.
How PreCheck Actually Works
PreCheck flips the traditional sequence on its head. Instead of building a facility, filing your application, and then hoping the FDA likes what it sees, selected companies get ongoing FDA input during construction.
The program has two phases. In Phase 1 (Facility Readiness), companies submit detailed information about their facility through a specialized Drug Master File, essentially a regulatory dossier covering everything from building layout and equipment strategy to quality systems and data integrity controls. The FDA reviews this package and provides technical feedback while concrete is still being poured and equipment is still being installed.
In Phase 2 (Application Submission), when a company links the facility to an actual drug application (like a new drug or biologics license filing), the FDA uses all that Phase 1 knowledge to streamline its manufacturing review. Inspections can be planned earlier. Quality issues that might have been surprises are already resolved.
The potential payoff? Up to 14 months saved on facility readiness, according to the FDA's own estimates. For a blockbuster biologic, 14 months of earlier revenue is worth billions.
A Regulatory First, Not Just Another Fast Track
It's tempting to lump PreCheck in with existing FDA speed programs like Fast Track, Breakthrough Therapy, or RMAT (Regenerative Medicine Advanced Therapy) designation. But PreCheck is a fundamentally different animal. Those programs accelerate the clinical side of drug development: more FDA meetings, rolling reviews, senior leadership involvement. They're about the science.
PreCheck accelerates the manufacturing side. It doesn't change any approval standards or guarantee faster reviews. It reduces the chance that a perfectly good drug gets stuck in limbo because its factory wasn't ready for prime time.
Think of it this way: Breakthrough Therapy is like getting a tutor for the final exam. PreCheck is like getting the answer key to the building code before you start construction.
The Competitive Moat Nobody's Talking About
The most interesting part of this program isn't the regulatory mechanics; it's the competitive dynamics. Only seven companies got in. Future cohorts are planned, but no dates have been announced. That means these seven firms now have a first-mover advantage in understanding how PreCheck works, what the FDA expects, and how to structure their facilities accordingly.
For the big players like Lilly and Regeneron, this is incrementally positive. Their manufacturing machines are already massive. But for smaller participants like Kriya Therapeutics (gene therapy) and Cellares (automated cell processing), selection is a powerful credibility signal. It tells partners, investors, and potential customers that the FDA considers their facilities worth engaging with early.
FUJIFILM Biotechnologies presents an especially interesting case. As a contract manufacturer (CDMO), its PreCheck participation could let its clients benefit from faster facility assessments. That's a compelling sales pitch: "Build your drug at our FDA-pre-vetted facility."
The Bigger Picture: Bringing Pharma Home
PreCheck didn't emerge in a vacuum. It was born from an Executive Order directing the FDA to support domestic pharmaceutical manufacturing and supply chain resilience. After decades of offshoring drug production, the U.S. government is now actively incentivizing companies to build here.
The selection criteria reinforce this. The FDA weighted applications based on products to be manufactured, innovation in facility development, and whether the facility addresses critical medicines, drug shortages, or supply-vulnerable products. Companies had to commit to manufacturing at the facility for at least three years after approval.
The selected facilities span an impressive range of capabilities: small-molecule sterile liquids, cell and gene therapies, biologics, biotech drug substance, sterile injectables, and API manufacturing. It's a cross-section of nearly everything the U.S. wants to make more of domestically.
What to Watch Next
Pre-operational engagements officially began on July 1, 2026. The real test will come when the first PreCheck participant files a drug application referencing one of these facilities. Will the manufacturing review actually go faster? Will the inspection process feel less like a surprise audit and more like a collaborative checkpoint?
If it works, expect a stampede of applications for the next cohort. Every major pharma company building a new U.S. facility will want in. And for complex biologics and gene therapies, where manufacturing has always been the Achilles' heel, PreCheck could quietly become one of the most important regulatory innovations in years.
It's not as sexy as a breakthrough cancer drug. But getting that cancer drug to patients 14 months faster? That's worth paying attention to.
Clinical & Regulatory
4 min read
The First Toddlers Eligible for CRISPR Are Two Years Old
The FDA just approved a CRISPR gene therapy for kids as young as two, making Casgevy the first gene-editing treatment cleared for toddlers with sickle cell disease or beta thalassemia. The approval took just 53 days, and the implications stretch far beyond the 5,500 newly eligible children.
